Pipeline

Solid Tumors

PNT2004

Clinical Candidate: PNT6555

Preclinical
Lu
Lutetium
(177)
71
Ac
Actinium
(225)
89

PNT2004 is an early-stage radioligand that targets Fibroblast Activation Protein-α (FAP-α), which is highly expressed on a wide range of solid tumors. PNT2004 was developed in collaboration with Dr. William Bachovchin at Tufts, a leader in designing inhibitors of DASH family proteases, including FAP.

FAP-α is a compelling pan-cancer target for imaging and therapy because it is found in greater than 90% of epithelial tumors.

PNT2004 targets FAP-α with best-in-class tumor retention and normal tissue clearance, exhibiting ideal radiopharmaceutical characteristics: delivery of large doses of radiation directly to a wide variety of tumors while being flushed from healthy tissues.

POINT intends to initiate a Phase 1 trial for PNT2004 in 2022.